2025 Non-Alcoholic Steatohepatitis (NASH) Market Outlook: Opportunities, Growth Drivers, and Strategic Analysis
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Non-Alcoholic Steatohepatitis (NASH) Sector?
The market size for non-alcoholic steatohepatitis (NASH) has witnessed remarkable growth in recent years. This market is set to expand from $4.5 billion in 2024 to $6.06 billion in 2025, with a compound annual growth rate (CAGR) of 34.7%. Factors such as an escalating prevalence of NASH, the obesity crisis, increasing awareness and diagnosis, transformation in lifestyle and food habits, and progression of healthcare infrastructure have contributed to the growth during the historic period.
In the upcoming years, the market size of non-alcoholic steatohepatitis (NASH) is predicted to experience significant growth, reaching “$18.55 billion in 2029 with a compound annual growth rate (CAGR) of 32.3%“. The expected growth in the forecasting period is largely due to factors such as advancements in NASH drug development, heightened initiatives for NASH screening, growing healthcare expenditure, joint research efforts, as well as governmental support and regulations. In the forecast period, the major trends that will affect the market include an emphasis on lifestyle modifications and patient education, an increased collaboration in clinical studies, advancements in regulations and pathway designations, and the implementation of artificial intelligence in diagnosis and monitoring.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
What Forces Are Driving The Growth Of The Non-Alcoholic Steatohepatitis (NASH) Market?
The surge in obesity prevalence is fuelling a considerable demand for the non-alcoholic steatohepatitis (NASH) market. Obesity involves abnormal or excessive fat accumulation that carries health risks, including a body weight exceeding the healthy or normal limit for an individual’s height. The escalating obesity crisis is leading to a higher incidence of non-alcoholic fatty liver disease, which in turn might make NASH the leading cause of serious liver disease in the coming years. This trend underpins the growing need for NASH treatment and related medications. For example, the World Health Organization (WHO), a UK-based global public health body, stated in March 2024 that nearly 2.5 billion adults aged 18 and above were overweight in 2022, with around 890 million of them suffering from obesity. Thus, the increasing obesity rates are anticipated to propel the growth of the non-alcoholic steatohepatitis (NASH) market.
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Which Trends Are Redefining The Future Landscape Of The Non-Alcoholic Steatohepatitis (NASH) Industry?
Leading corporations in the non-alcoholic steatohepatitis (NASH) market are concentrating on the development of thyroid hormone receptor-beta (THR-beta) agonists. These agonists are designed to improve liver metabolism, decrease liver fat buildup, and enhance liver function. The THR-beta agonists work by selectively triggering the thyroid hormone receptor-beta subtype, a critical receptor controlling metabolism, growth, and development. For instance, in March 2024, the US-based regulatory body, the Food and Drug Administration, sanctioned the first treatment for adults with noncirrhotic NASH with medium to severe liver scarring (fibrosis), Rezdiffra (resmetirom), a THR-beta agonist. Rezdiffra functions by selectively activating the THR-beta receptor, which helps manage lipid metabolism, resulting in a decrease in intrahepatic triglycerides and liver fat buildup.
Which Companies Currently Dominate The Competitive Landscape In The Non-Alcoholic Steatohepatitis (NASH) Industry?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
Which Geographic Regions Are Driving Demand In The Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
